GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Upper GI Tract/FOXM1 Blockade Restores Epithelial Homeostasis in EoE : Gut | 2026

FOXM1 Blockade Restores Epithelial Homeostasis in EoE : Gut | 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated May 1, 2026

Quick Answer

Introduction Eosinophilic oesophagitis (EoE) is a chronic Th2-mediated inflammatory disease characterized by epithelial barrier dysfunction, basal cell hyperplasia and persistent mucosal remodeling. Even after inflammatory control, epithelial transcriptomic and histologic abnormalities often persist, contributing to ongoing symptoms and disease relapse.


Introduction

Eosinophilic oesophagitis (EoE) is a chronic Th2-mediated inflammatory disease characterized by epithelial barrier dysfunction, basal cell hyperplasia and persistent mucosal remodeling. Even after inflammatory control, epithelial transcriptomic and histologic abnormalities often persist, contributing to ongoing symptoms and disease relapse. Identifying molecular regulators of epithelial dysfunction remains a major therapeutic priority.

Problem Statement

Current EoE therapies primarily target inflammation but incompletely restore epithelial homeostasis. The mechanisms linking IL-13-driven inflammation to impaired epithelial differentiation and excessive proliferation are incompletely understood, limiting development of therapies that promote durable mucosal healing.

Summary

This translational study identifies forkhead box M1 (FOXM1) as a central transcriptional regulator of epithelial remodeling in EoE. FOXM1 expression was markedly increased in active EoE and localized predominantly to the basal epithelial layer. IL-13 stimulation upregulated FOXM1 in oesophageal epithelial cells, organoids and murine EoE models, linking Th2 inflammation directly to epithelial proliferative signaling. Functional inhibition of FOXM1 using the small-molecule inhibitor RCM-1 or siRNA restored epithelial differentiation markers including involucrin and filaggrin, reduced basal cell hyperplasia, suppressed proliferation and improved epithelial barrier integrity. In murine EoE models, FOXM1 inhibition reduced eosinophilic inflammation and reversed histologic remodeling. Mechanistically, FOXM1 directly regulated the cell-cycle gene cyclin B1 (CCNB1), driving epithelial proliferation through altered G2/M transition. The study further demonstrated that IL-13 activates a non-canonical PI3K/AKT–FOXM1 signaling axis, while FOXM1 inhibition reduced STAT6 phosphorylation and suppressed eotaxin-3 (CCL26) expression, indicating simultaneous modulation of epithelial and inflammatory pathways. Importantly, FOXM1 overexpression independently induced epithelial hyperplasia and proliferation even without IL-13 stimulation, reinforcing its pathogenic role. These findings position FOXM1 as a novel therapeutic target capable of simultaneously restoring epithelial differentiation, improving barrier function and attenuating allergic inflammation in EoE. The work also highlights a paradigm shift toward epithelial-directed therapeutic strategies in EoE beyond eosinophil suppression alone.

Related Q&A

Basal Crypt Dysplasia in Barrett's Esophagus: GUT | July 2026

Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may...

High-Resolution Impedance Manometry after POEM: AJG | May 2026

Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological...

Magnetic Sphincter Augmentation Provides Durable GERD Control : Ann Surg | Jun 2026

Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving...

New Strategies Needed for Resistant H. pylori : Indian J Gastroenterol | Jun 2026

Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice,...

Vonoprazan–Tetracycline Dual Therapy Simplifies H. pylori Rescue Treatment : Gastroenterology | June 2026

Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and...

H. pylori Eradication Reduces Cancer but Mortality Benefit Remains Fragile : Gastroenterology | June 2026

Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer